Nicotine diminishes anticonvulsant acitivity of antiepileptic drugs in mice

Polish Journal of Pharmacology

Volumn 55, Issue 5, 2003, Pages 799-802

  Czuczwar, Mirosław ^a   Kiś, Jacek ^a   Czuczwar, Piotr ^a   Wielosz, Marian ^a   Turski, Waldemar ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Nicotine; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; NICOTINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; ELECTRIC SHOCK; MALE; MOUSE; NONHUMAN; TONIC SEIZURE; TREATMENT FAILURE;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROSHOCK; FRUCTOSE; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; NICOTINE; PHENOBARBITAL; PHENYTOIN; SEIZURES; TRIAZINES; VALPROIC ACID;

EID: 0347996121     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Arun P., Ravikumar A., Leelamma S., Kurup P.A.: Endogenous alkaloids in the brain of rats loaded with tyrosine/tryptophan and in the serum of patients of neurodegenerative and psychiatric disorders. Indian J. Med. Res., 1998, 107, 231-238.
2. Broide R.S., Salas R., Ji D., Paylor R., Patrick J.W., Dani J.A., De Biasi M.: Increased sensitivity to nicotine-induced seizures in mice expressing the L250T alpha 7 nicotinic acetylcholine receptor mutation. Mol. Pharmacol., 2002, 61, 695-705.
3. Czemin J., Waldherr C.: Cigarette smoking and coronary blood flow. Prog. Cardiovasc. Dis., 2003, 45, 395-404.
4. Damaj M.I., Glassco W., Dukat M., Martin B.R.: Pharmacological characterisation of nicotine-induced seizures in mice. J. Pharmacol. Exp. Ther., 1999, 291, 1284-1291.
5. Fonck C., Nashmi R., Deshpande P., Damaj M.I., Marks M.J., Riedel A., Schwarz J., Collins A.C., Labarca C., Lester H.A.: Increased sensitivity to agonist-induced seizures, straub tail, and hippocampal theta rhythm in knock-in mice carrying hypersensitive alpha 4 nicotinic receptors. J. Neurosci., 2003, 23, 2582-2590.
6. Gil Z., Sack R.A., Kedmi M., Harmelin A., Orr-Urtreger A.: Increased sensitivity to nicotine-induced seizures in mice heterozygous for the L250T mutation in the alpha7 nicotinic acetylcholine receptor. Neuroreport, 2002, 13, 191-196.
7. Hecht S.S.: Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol., 2002, 3, 461-469.
8. Hogg R.C., Raggenbass M., Bertrand D.: Nicotinic acetylcholine receptors: from structure to brain function. Rev. Physiol. Biochem. Pharmacol., 2003, 147, 1-46.
9. Kis J., Czuczwar M., Zielinska E., Bojar I., Czuczwar S.J., Turski W.A.: Kynurenic acid does not protect against nicotine-induced seizures in mice. Pol. J. Pharmacol., 2000, 52, 477-480.
10. Kwan P., Brodie M.J.: Early identification of refractory epilepsy. N. Engl. J. Med., 2000, 342, 314-319.
11. Kwan P., Brodie M.J.: Refractory epilepsy: a progressive, intractable but preventable condition? Seizure, 2002, 11, 77-84.
12. Kyngas H.: Compliance with health regimens of adolescents with epilepsy. Seizure, 2000, 9, 598-604.
13. Levin E.D., Rezvani A.H.: Nicotinic treatment for cognitive dysfunction. Curr. Drug Target CNS Neurol. Disord., 2002, 1, 423-431.
14. Litchfield J.T., Wilcoxon F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 1949, 96, 99-113.
15. Loscher W, Potschka H., Wlaz P., Danysz W., Parsons C.G.: Are neuronal nicotinic receptors a target for antiepileptic drug development? Studies in different seizure models in mice and rats. Eur. J. Pharmacol., 2003, 466, 99-111.
16. Mahoney G.N., Al-Delaimy W.: Measurement of nicotine in hair by reversed-phase high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B-Biomed. Appl., 2001, 753, 179-187.
17. Moulard B., Picard F., le Hellard S., Agulhon C., Weiland S., Favre I., Bertrand S., Malafosse A., Bertrand D.: Ion channel variation causes epilepsies. Brain Res. Rev., 2001, 36, 275-284.
18. Oddoze C., Pauli A.M., Pastor J.: Rapid and sensitive high-performance liquid chromatographic determination of nicotine and cotinine in nonsmoker human and rat urines. J. Chromatogr. B-Biomed. Appl., 1998, 708, 95-101.
19. Quik M., Kulak J.M.: Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology, 2002, 23, 581-594.
20. Ravikumar A., Arun P., Devi K.V., Kurup P.A.: Endogenous strychnine, nicotine, and morphine - description of hypo- and hyper-strychninergic, nicotinergic and morphinergic state in relation to neuropsychiatric diseases. Indian J. Exp. Biol., 2000, 38, 559-566.
21. Salas R., Orr-Urtreger A., Broide R.S., Beaudet A., Paylor R., De Biasi M.: The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo. Mol. Pharmacol., 2003, 63, 1059-1066.
22. Sandborn W.J.: Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Amer. J. Gastroenterol., 1999, 94, 1161-1171.
23. Tischler D.M., Weinberg K.I., Hinton D.R., Barbaro N., Annett G.M., Raffel C.: MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia, 1995, 36, 1-6.